Background Systemic lupus erythematosus (SLE) and systemic vasculitis are autoimmune diseases. SLE is of an unknown cause that occurs primarily in women and can involve many organs. Systemic vasculitis is characterized by inflammatory destruction of the blood vessels and tissue necrosis, there are several types of vasculitis classified by size of the affected blood vessels. Mycophenolate mofetil (MMF) is an immunosuppressive drug that is commonly used within the transplantation area, but also for autoimmune systemic diseases such as SLE and systemic vasculitis.
Objectives The aim of this study was to investigate the outcome of MMF in patients with SLE and systemic vasculitis.
Methods This study included patients with SLE or systemic vasculitis with ongoing or previous MMF treatment at Karolinska University Hospital, Stockholm, Sweden. Data on specific information regarding disease and treatment was obtained through medical record review.
Results Out of a total of 648 patients with SLE and 455 with systemic vasculitis; 135 patients (21%) with SLE and 43 patients (9%) with vasculitis had ongoing or previous MMF treatment. The most common organ manifestation at baseline was renal involvement (50%) among SLE patients. Median MMF dose was 2g/day and glucocorticoids (GC) doses were significantly reduced during MMF treatment from 21.7 mg/day to 8.3 mg/day after 12 months. By physician assessment, 79% of the patients were good or moderate responders to MMF treatment after 12 months. The most common adverse events leading to discontinuation were side effects in the gastrointestinal tract (40%) and general side effects (30%). A “survival-on-drug” Kaplan-Meier curve showed that 40% of the patients remained on long-term MMF treatment.
Conclusions MMF was used in 16% of all patients with SLE and systemic vasculitis. The treatment appeared to be effective with a reasonable survival-on-drug as well as a GC sparing effect for many patients with SLE or systemic vasculitis.
Disclosure of Interest C. Lourdudoss: None Declared, S. Jamil: None Declared, R. van Vollenhoven Grant/research support from: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB, Consultant for: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB